Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Purple Biotech Q4 EPS $(0.19), Inline

Author: Benzinga Newsdesk | March 05, 2024 08:58am

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 36.67 percent increase over losses of $(0.30) per share from the same period last year.

Posted In: PPBT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist